Data updated: Jun 28, 2026
ADHD Clinical Trial Landscape
ADHD is being studied across 333 clinical trials registered since 2008, with 39 programs currently active. The competitive pipeline includes 9 active Phase 3 trials, 10 active Phase 2 trials, and 3 active Phase 1 trials.
Top industry sponsors include Otsuka Pharmaceutical Co., Ltd., Boehringer Ingelheim, Bazelet Nehushtan LtD..
Trial activity
39 active / 333 total since 2008
Active by phase 9 Ph3 / 118 10 Ph2 / 73 3 Ph1 / 34 17 Ph4 / 108
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
Otsuka Pharmaceutical Co., Ltd. 4 0 0
Boehringer Ingelheim 1 0 0
Bazelet Nehushtan LtD. 1 0 0
Takeda 0 20 2
Supernus Pharmaceuticals, Inc. 0 14 4
Otsuka Pharmaceutical Development & Commercialization, Inc. 0 13 1
Eli Lilly 0 9 3
Sumitomo Pharma America, Inc. 0 11 0
Rhodes Pharmaceuticals, L.P. 0 8 0
Alcobra Ltd. 0 5 1
Aevi Genomic Medicine, LLC, a Cerecor company 0 5 0
Tris Pharma, Inc. 0 5 0
Pfizer 0 2 3
Cingulate Therapeutics 0 3 1
Neurocentria, Inc. 0 1 2
How the field has grown
New-trial starts peaked in 2018 (20 registered); 2025 saw 13. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (52 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 18
2017 18
2018 20
2019 19
2020 10
2021 6
2022 5
2023 9
2024 15
2025 13
2026 7
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (6) 215
2017 (11) 156
2018 (6) 212
2019 (7) 374
2020 (3) 240
2021 (2) 108
2022 (1) 21
2023 (5) 103
2024 (6) 70
2025 (5) 315
2026 (0) 0
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT07086313 RECRUITING
A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
Otsuka Pharmaceutical Co., Ltd. n=315
NCT07087327 RECRUITING
A Long-term Trial of EB-1020 in Pediatric Patients With ADHD
Otsuka Pharmaceutical Co., Ltd. n=180
NCT06931080 RECRUITING
Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients
Otsuka Pharmaceutical Co., Ltd. n=630
NCT06926829 RECRUITING
A Long-term Trial of EB-1020 in Adult Patients With ADHD
Otsuka Pharmaceutical Co., Ltd. n=180
NCT04704687 RECRUITING
Clinical Efficacy and Long Term Effects of Transcranial Direct Current Stimulation (tDCS) in Children With Attention Deficit/Hyperactivity Disorder (ADHD)
Centre Hospitalier Universitaire, Amiens n=150
NCT04240756 ACTIVE NOT RECRUITING
Treating Parents with ADHD and Their Young Children Via Telehealth: a Hybrid Type I Effectiveness-Implementation Trial
University of Maryland, College Park n=240
NCT05832489 RECRUITING
EEG-MRI Imaging of Methylphenidate Effects in Adult ADHD and Attentional Symptoms in Mood Disorders
University Hospital, Strasbourg, France n=80
NCT06973577 COMPLETED
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Otsuka Pharmaceutical Development & Commercialization, Inc. n=315
NCT05924594 SUSPENDED
Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301
Cingulate Therapeutics n=45
NCT05386251 WITHDRAWN
Effectiveness of a Digital Strategy-based Educational Skills Group for Secondary Students With Organization and Academic Motivation Challenges
Seattle Children's Hospital
NCT05972044 COMPLETED
A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
Axsome Therapeutics, Inc. n=516
NCT05286762 COMPLETED
Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
Cingulate Therapeutics n=103
NCT06215144 TERMINATED
Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD
Neurocentria, Inc. n=95
NCT06454604 COMPLETED
Virtual Reality Treatment for Emerging Adults With ADHD
Rutgers, The State University of New Jersey n=60
NCT06431256 TERMINATED
Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD
Ironshore Pharmaceuticals and Development, Inc n=26
NCT06854601 COMPLETED
Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12
Pharmasoft n=333
NCT05631626 COMPLETED
Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.
Cingulate Therapeutics n=21
NCT02348073 COMPLETED
Efficacy of Phosphatidylserine Enriched With n-3 PUFA Supplementation on ADHD in Children With Epilepsy
Hospices Civils de Lyon n=77
NCT05683249 COMPLETED
Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)
Neurocentria, Inc. n=223
NCT03605849 COMPLETED
A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc. n=662
NCT03659929 COMPLETED
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
Arbor Pharmaceuticals, Inc. n=320
NCT01351272 COMPLETED
Genetic Modulation of Working Memory in Attention Deficit Hyperactivity Disorder (ADHD)
Wuerzburg University Hospital n=41
NCT04569357 COMPLETED
Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children
Materia Medica Holding n=363
NCT02691182 TERMINATED
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
Supernus Pharmaceuticals, Inc. n=491
NCT03597503 TERMINATED
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
Supernus Pharmaceuticals, Inc. n=41
NCT02618434 COMPLETED
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
Supernus Pharmaceuticals, Inc. n=297
NCT04839562 COMPLETED
A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults
Massachusetts General Hospital n=66
NCT06006871 COMPLETED
Effectiveness of the Serious Video Game MOON in Emotional Regulation in ADHD
Puerta de Hierro University Hospital n=76
NCT02618408 COMPLETED
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
Supernus Pharmaceuticals, Inc. n=333
NCT03834766 COMPLETED
Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD
Tris Pharma, Inc. n=130
NCT02502799 TERMINATED
Intervention for Teens With ADHD and Substance Use
Florida International University n=158
NCT01239030 COMPLETED
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
Rhodes Pharmaceuticals, L.P. n=230
NCT01269463 COMPLETED
Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting
Rhodes Pharmaceuticals, L.P. n=26
NCT04016779 COMPLETED
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
Supernus Pharmaceuticals, Inc. n=374
NCT03481959 TERMINATED
Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity
Assistance Publique - Hôpitaux de Paris n=3
NCT01883817 COMPLETED
Effect of Omega-3 Fatty Acid on Cortical Function in ADHD
University of Cincinnati n=30
NCT03605680 COMPLETED
A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc. n=604
NCT02704390 COMPLETED
Evaluate Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
Orient Pharma Co., Ltd. n=64
NCT02450890 COMPLETED
Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
Orient Pharma Co., Ltd. n=114
NCT03605836 COMPLETED
A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc. n=590
NCT02777931 COMPLETED
Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
Aevi Genomic Medicine, LLC, a Cerecor company n=101
NCT03618030 COMPLETED
PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Purdue Pharma, Canada n=288
NCT02520388 COMPLETED
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting
Ironshore Pharmaceuticals and Development, Inc n=163
NCT02493777 COMPLETED
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
Ironshore Pharmaceuticals and Development, Inc n=125
NCT03460652 COMPLETED
KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD
Zevra Therapeutics n=282
NCT03247543 COMPLETED
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD
Supernus Pharmaceuticals, Inc. n=313
NCT03247556 COMPLETED
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD
Supernus Pharmaceuticals, Inc. n=297
NCT03247530 COMPLETED
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD
Supernus Pharmaceuticals, Inc. n=477
NCT01244490 COMPLETED
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Shire n=338
NCT03292952 COMPLETED
KP415 Classroom Study in Children (6-12 Years of Age) With ADHD
Zevra Therapeutics n=155
NCT02255513 COMPLETED
A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD
Ironshore Pharmaceuticals and Development, Inc n=43
NCT03247517 COMPLETED
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD
Supernus Pharmaceuticals, Inc. n=310
NCT01500694 COMPLETED
Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe
Shire n=215
NCT00763971 COMPLETED
Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17
Shire n=336
NCT00735371 COMPLETED
Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
Shire n=314
NCT00734578 COMPLETED
Efficacy and Safety of SPD503 in Combination With Psychostimulants
Shire n=461
NCT00697515 COMPLETED
Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Shire n=142
NCT00784654 COMPLETED
Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17
Shire n=276
NCT03260205 COMPLETED
Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Shire n=199
NCT03325894 TERMINATED
Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Shire n=141
NCT02604407 COMPLETED
Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)
Shire n=275
NCT02466425 COMPLETED
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Shire n=264
NCT01274221 WITHDRAWN
Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Shire
NCT03325881 COMPLETED
Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
Shire n=89
NCT02466386 COMPLETED
Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder
Shire n=113
NCT02083783 COMPLETED
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
Tris Pharma, Inc. n=108
NCT03231800 COMPLETED
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Sumitomo Pharma America, Inc. n=95
NCT02734693 COMPLETED
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Sumitomo Pharma America, Inc. n=132
NCT01796262 COMPLETED
The Effects of DHA on Attention Deficit and Hyperactivity Disorder
IRCCS Eugenio Medea n=50
NCT03172481 COMPLETED
PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD
Purdue Pharma, Canada n=156
NCT00965419 TERMINATED
A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder
Eli Lilly and Company n=267
NCT04016792 WITHDRAWN
Classroom Study of SPN-812 in Children With ADHD
Supernus Pharmaceuticals, Inc.
NCT03088267 COMPLETED
Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study
Tris Pharma, Inc. n=18
NCT02139124 COMPLETED
The Efficacy and Safety of PRC-063 in Adult ADHD Patients
Rhodes Pharmaceuticals, L.P. n=375
NCT03662763 COMPLETED
Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity
Maastricht University Medical Center n=12
NCT00723190 COMPLETED
Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Shionogi n=303
NCT01835548 COMPLETED
NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
Neos Therapeutics, Inc n=87
NCT01853280 COMPLETED
L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults
Massachusetts General Hospital n=47
NCT00857220 COMPLETED
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Sumitomo Pharma America, Inc. n=304
NCT01340690 TERMINATED
Efficacy Study of Polyunsaturated Fatty Acids in Children and Adolescents With Attention Deficit/ Hyperactivity Disorder
Johannes Gutenberg University Mainz n=284
NCT01109849 COMPLETED
Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth
Florida International University n=230
NCT01000064 TERMINATED
Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits
Vanderbilt University n=22
NCT02160262 COMPLETED
Open-label Safety Study in Adults With ADHD
Sumitomo Pharma America, Inc. n=724
NCT01344044 COMPLETED
Brain-Computer Interface (BCI) Based Intervention for Attention Deficit Hyperactivity Disorder (ADHD)
National Healthcare Group, Singapore n=192
NCT02059642 COMPLETED
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
Alcobra Ltd. n=300
NCT02477748 TERMINATED
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
Alcobra Ltd. n=283
NCT02555150 COMPLETED
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
Rhodes Pharmaceuticals, L.P. n=40
NCT01654250 COMPLETED
NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)
Pfizer n=90
NCT01022229 COMPLETED
The Safety and Efficacy of a Compound Natural Health Product in Children With Attention Deficit Hyperactivity Disorder (ADHD)
The Canadian College of Naturopathic Medicine n=16
NCT01363544 COMPLETED
Train Your Brain and Exercise Your Heart? Advancing the Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
R. van Mourik n=112
NCT00704990 COMPLETED
Combination Natural Health Product in Children With Attention Deficit/Hyperactivity Disorder (ADHD)
Kieran Cooley n=28
NCT02168127 COMPLETED
Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD
Rhodes Pharmaceuticals, L.P. n=360
NCT01777048 TERMINATED
Omega-3 Fatty Acids Supplementation in ADHD
University Hospital, Basel, Switzerland n=8
NCT01675804 COMPLETED
Computer-assisted Cognitive Rehabilitation (CACR), Placebo CACR and Psycho-stimulants in the Treatment of ADHD
Allameh Tabatabai University n=34
NCT00922636 COMPLETED
A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder
Eli Lilly and Company n=340
NCT00904670 COMPLETED
Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Pfizer n=45
NCT00700427 COMPLETED
A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Eli Lilly and Company n=2,017
NCT00782080 COMPLETED
Efficacy and Safety of St. John´s Wort/Valerian Extract Versus Placebo in Children and Adolescents With ADHD
Prof. Huss n=155
NCT00856973 COMPLETED
Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Sumitomo Pharma America, Inc. n=486
NCT01855984 COMPLETED
Tocotrienols for School-going Children With ADHD
RCSI & UCD Malaysia Campus n=160
NCT00969618 COMPLETED
A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder
Eli Lilly and Company n=211
NCT01738334 COMPLETED
Effects Of The Mindfulness Meditation Practices On Cognition
Federal University of São Paulo n=40
NCT00962104 COMPLETED
Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder
Eli Lilly and Company n=391
NCT00641329 COMPLETED
CLONICEL (Clonidine Sustained Release) as Add-on to Stimulant Medication in 6 to 17 Yr-olds With ADHD
Addrenex Pharmaceuticals, Inc. n=198
NCT00730249 COMPLETED
Quality Assurance of Administering Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD) - QUMEA
Medice Arzneimittel Pütter GmbH & Co KG n=150
NCT06359899 COMPLETED
A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD
Shanghai Ark Biopharmaceutical Co., Ltd. n=55
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only